Venlafaxine in the Treatment of Premenstrual Dysphoric Disorder

@article{Freeman2001VenlafaxineIT,
  title={Venlafaxine in the Treatment of Premenstrual Dysphoric Disorder},
  author={E. Freeman and K. Rickels and K. Yonkers and N. Kunz and M. McPherson and G. V. Upton},
  journal={Obstetrics \& Gynecology},
  year={2001},
  volume={98},
  pages={737–744}
}
OBJECTIVE To evaluate the efficacy and safety of venlafaxine, a new‐generation antidepressant that selectively inhibits serotonin and norepinephrine reuptake, in the treatment of premenstrual dysphoric disorder (PMDD). METHOD We conducted a randomized, double‐blind, placebo‐controlled, parallel‐group, flexible‐dose trial. After three screening cycles, including a single‐blind placebo cycle, 164 women were randomly assigned to double‐blind treatment with venlafaxine (50–200 mg/day) or placebo… Expand
Effective open‐label treatment of premenstrual dysphoric disorder with venlafaxine
  • M. Hsiao, C. Liu
  • Psychology, Medicine
  • Psychiatry and clinical neurosciences
  • 2003
TLDR
It is indicated that venlafaxine is effective in the treatment of ethnic Taiwanese women with PMDD, and patients had significant improvement of the mood and behavior components in the PRISM calendar. Expand
Efficacy and Tolerability of Premenstrual Use of Venlafaxine (Flexible Dose) in the Treatment of Premenstrual Dysphoric Disorder
TLDR
It is suggested that premenstrual use of venlafaxine is an efficacious and well-tolerated treatment for pre menstrual dysphoric disorder. Expand
Duloxetine for premenstrual dysphoric disorder: a pilot study
TLDR
Duloxetine 60 mg/day was effective in reducing PMDD symptoms and generally well tolerated and the results appeared to be strong and consistent across measures. Expand
Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder
TLDR
Fluoxetine is generally a well-tolerated treatment for PMDD and discontinuation effects have not been reported with intermittent dosing regimens. Expand
The pharmacologic management of premenstrual dysphoric disorder
TLDR
Due to the unique pathophysiology of the disorder, the selective serotonin re-uptake inhibitors can be effectively administered intermittently, with dosing limited to the luteal phase of the cycle (2 weeks prior to menses). Expand
Premenstrual Dysphoric Disorder
TLDR
Premenstrual dysphoric disorder is characterized by mood, appetite, energy, and cognitive changes that occur during the late luteal phase of the menstrual cycle and remit shortly after the onset of menses. Expand
Treatment of Premenstrual Dysphoric Disorder
TLDR
Treatment of PMDD and severe premenstrual syndrome has centered on neuromodulation via serotonin reuptake inhibitor antidepressants, and ovulation suppression utilizing various contraceptive and hormonal preparations. Expand
Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline
Sertraline (Zoloft™, Pfizer Inc.) is a selective serotonin re-uptake inhibitor (SSRI) which has been approved by the US FDA for the treatment of premenstrual dysphoric disorder (PMDD). PMDD is aExpand
A review of treatment of premenstrual syndrome & premenstrual dysphoric disorder
  • A. Rapkin
  • Medicine
  • Psychoneuroendocrinology
  • 2003
TLDR
Preliminary evidence suggests that the drospirenone-containing pill called Yasmin may be effective the treatment of PMDD, and there is good clinical evidence for GnRH analogs with addback hormonal therapy, danocrine, and estradiol implants or patches with progestin to protect the endometrium. Expand
Management Strategies for Premenstrual Syndrome/Premenstrual Dysphoric Disorder
TLDR
Healthcare providers need to be aware of the symptoms of PMS and PMDD and the treatment options available and treatment selection should be based on Individual patient symptoms, concomitant medical history, and need for contraception. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder.
TLDR
Fluoxetine was significantly superior to bupropion and placebo as an effective treatment for PMDD, and patient satisfaction was far greater with fluoxettine. Expand
Fluoxetine in the Treatment of Premenstrual Dysphoria
TLDR
Fluoxetine is an effective treatment of PMDD and the ability of the acute behavioral response to luteal phase m-CPP administration to predict therapeutic response to fluoxetines is evaluated. Expand
Symptomatic Improvement of Premenstrual Dysphoric Disorder With Sertraline Treatment: A Randomized Controlled Trial
TLDR
Serotonin reuptake inhibitors such as sertraline are useful therapeutic options for women with premenstrual dysphoria as reflected by symptomatic improvement and change in reported functional impairment. Expand
Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo‐controlled trial
TLDR
It is concluded that low doses of clomipramine effectively reduce premenstrual irritability and dysphoria with a response rate close to 100%. Expand
Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study.
TLDR
Luteal phase treatment with sertraline was a safe and effective treatment for moderate-to-severe premenstrual dysphoric disorder and a repeated-measures analysis of variance for crossover designs found a significant beneficial effect from sERTraline treatment in improving the calendar of pre menstrual experiences. Expand
Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial.
TLDR
The comparison of 2 classes of antidepressants strongly favored the serotonergic drug, which effectively reduced symptoms and improved functioning and was well tolerated by women with severe premenstrual syndrome. Expand
Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant.
TLDR
This preliminary randomized, double-blind study compared the responses to half-cycle or full-cycle dosing of sertraline in 31 patients who completed a preceding double- blind, short-term treatment trial for premenstrual syndrome (PMS). Expand
Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome.
TLDR
Luteal phase treatment in women with dysphoric PMS produced significant improvements in depression, impairment, and global ratings compared with placebo and was equivalent in efficacy to sertraline given during the entire menstrual cycle. Expand
Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial.
TLDR
This study is the first to demonstrate a significant response to a serotonin selective reuptake inhibitor used only during the luteal phase of the menstrual cycle, and points out the importance of this finding both in terms of economic cost of patients as well as how it may add to the growing understanding of the etiology of PMDD. Expand
Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review
TLDR
SSRIs were effective in treating physical and behavioural symptoms and there was no significant difference in symptom reduction between continuous and intermittent dosing or between trials funded by pharmaceutical companies and those independently funded. Expand
...
1
2
3
...